A Study of Patients with Kawasaki Disease who Required an Additional Immunoglobulin Therapy

被引:0
|
作者
Hirotaro Ogino
Shindo Okamoto
Toru Fujiwara
Masayuki Teraguchi
Yohnosuke Kobayashi
机构
[1] Kansai Medical University Rakusai New-town Hospital,Department of Pediatrics
[2] Kansai Medical University Hospital,Department of Pediatrics
来源
Pediatric Research | 2003年 / 53卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The subjects were 134 patients who received an initial immunoglobulin (IVIG) therapy in the acute phase of the disease from January 1990 to December 2000; 26 cases (19.4%) were prescribed an additional dosage of IVIG. The definition of the additional administration was either one of the followings: (1) when a patient received an initial IVIG therapy continuously for more than 5 days; (2) when the dosage of IVIG was increased during prescription; (3) when a patient received re-IVIG after the initial therapy. The coronary arterial lesion (CAL) was classified into four groups: no coronary lesion (N), mild coronary dilatation (Dil), middle-sized aneurysm (ANm), large aneurysm (ANl) based on echo-cardiography around the 30th day of illness. (1) The frequency (%) of CAL with and without additional IVIG was N: 65.4 vs 89.8, Dil: 3.8 vs 5.6, ANm: 19.2 vs 2.8, and ANl: 11.5 vs 1.9. (2) Percentage of cases who received additional IVIG in each category: (a) gender: male 18.4% and female 20.7%; (b) age at onset: subjects under 1 year of age or older than 4 years or more exceeded 20% in each age group; (c) start for initial IVIG therapy was as follows: the 2nd to 4th day of illness: 41.7%, the 5th to 7th day: 10.4% and the 8th day or more: 14.3%; (d) the first dosage (mg/kg) of IVIG were 100∼350: 50.0%, 351∼900: 18.2% and 901 or more: 8.3%.The two therapeutic characteristics obtained from the observations of the patients who required an additional IVIG were: (1) the start of the initial IVIG within the 4th day of illness and (2) the lower initial dosage of IVIG. In conclusion it was advisable to start the therapy from the 5th to 7th day of illness and to give a larger initial dose (more than 901mg/kg).
引用
收藏
页码:179 / 179
相关论文
共 50 条
  • [41] Pharmacological therapy for patients with Kawasaki disease
    Williams R.V.
    Minich L.L.
    Tani L.Y.
    Paediatric Drugs, 2001, 3 (9): : 649 - 660
  • [42] INTRAVENOUS IMMUNOGLOBULIN IN KAWASAKI DISEASE
    SALO, E
    PEDIATRIC RESEARCH, 1988, 24 (05) : 654 - 654
  • [43] Immunoglobulin Resistance in Kawasaki Disease
    Hartas, Georgios A.
    Hashmi, Syed Shahrukh
    Pham-Peyton, Chi
    Tsounias, Emmanouil
    Bricker, John T.
    Gupta-Malhotra, Monesha
    PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY, 2015, 28 (01) : 13 - 19
  • [44] Immunoglobulin A deficiency and Kawasaki disease
    Rowley, Anne H.
    Miura, Masaru
    PEDIATRICS INTERNATIONAL, 2010, 52 (02) : 330 - 330
  • [45] Immunoglobulin in suspected Kawasaki disease
    Garcia Soblechero, E.
    Gomez Santos, E.
    Dominguez Quintero, M. L.
    Gonzalez Vila, L.
    ANALES DE PEDIATRIA, 2010, 73 (03): : 151 - 152
  • [46] A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
    Li, Wei
    He, Xiufang
    Zhang, Li
    Wang, Zhouping
    Wang, Yanfei
    Lin, Huimei
    Yuan, Jia
    Xie, Xiaofei
    Qin, Youzhen
    Huang, Ping
    CARDIOVASCULAR THERAPEUTICS, 2021, 2021
  • [47] Neurological Prognosis Of Infliximab Therapy Against Immunoglobulin Refractory Kawasaki Disease
    Katsumata, Nobuyuki
    Kaga, Yoshimi
    Koizumi, Keiichi
    Toda, Takako
    Kise, Hiroaki
    Hasebe, Youhei
    Sugita, Kanji
    Hoshiai, Minako
    CIRCULATION, 2015, 131
  • [48] Functional mechanism of cyclosporin A therapy for immunoglobulin-resistant Kawasaki disease
    Kakimoto, Nobuyuki
    Suzuki, Hiroyuki
    Suenaga, Tomohiro
    Takeuchi, Takashi
    Shibuta, Shoichi
    Abe, Jun
    Yoshikawa, Norishige
    CIRCULATION, 2015, 131
  • [49] Association of Genetic Polymorphisms in Kawasaki Disease with the Response to Intravenous Immunoglobulin Therapy
    Sapountzi, E.
    Fidani, L.
    Giannopoulos, A.
    Galli-Tsinopoulou, A.
    PEDIATRIC CARDIOLOGY, 2023, 44 (01) : 1 - 12
  • [50] Persistent Endothelial Damage After Intravenous Immunoglobulin Therapy In Kawasaki Disease
    Sakurai, Yoshihiko
    Takatsuka, Hideo
    Takada, Mutsuzo
    Nishino, Masato
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB227 - AB227